Pelthos Therapeutics Inc.
AMEX: PTHS0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- New York Stock Exchange American
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Scott Plesha
- Employees
- 4
- Headquarters
- Durham, United States
- IPO year
- 2025
- Market cap
- $18.8M
- Website
- https://pelthos.com
Loading PTHS…
Loading profile data…Frequently asked questions about PTHS
What does Pelthos Therapeutics Inc. (PTHS) do?
Pelthos Therapeutics Inc. operates as a biopharmaceutical enterprise dedicated to developing and commercializing innovative medical treatments that address significant, unmet patient needs. Its primary offerings include ZELSUVMI, a medication specifically indicated for the treatment of molluscum contagiosum in individuals aged one year and older...
Where does PTHS trade?
Pelthos Therapeutics Inc. (PTHS) trades on the New York Stock Exchange American.
What sector is PTHS in?
Pelthos Therapeutics Inc. (PTHS) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Pelthos Therapeutics Inc.?
Scott Plesha is the chief executive officer of Pelthos Therapeutics Inc. (PTHS).
Where is Pelthos Therapeutics Inc. headquartered?
Pelthos Therapeutics Inc. is headquartered in United States.
Does PTHS pay a dividend?
Pelthos Therapeutics Inc. (PTHS) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did PTHS go public?
Pelthos Therapeutics Inc. (PTHS) completed its initial public offering in 2025.